Enteroviral Infection in Patients Treated with Rituximab for Non Hodgkin Lymphoma: a Case Series and Review of the Literature

The chimeric anti-CD20 monoclonal antibody rituximab is widely used for the treatment of B-cell lymphoproliferative disorders as well as for autoimmune diseases. Rituximab induces depletion of the peripheral B cell pool, leading to hypoglobulinemia which results in decreased antibody response to infections. Enteroviral infection can cause life-threatening meningoencephalitis and other systemic chronic syndromes in immune deficient patients

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sigal Grisariu, Pia Raanani, Ora Paltiel, Oren Pasvolsky, Iuliana Vaxman, Moshe Gatt, Shlomo Elias, Batia Avni, Ariella Arad Source Type: research